ROCHESTER, Minn. — A Mayo Clinic Comprehensive Cancer Center researcher will share findings from a late-breaking abstract at the 2024 Society of Urologic Oncology Annual Meeting in Dallas, Dec. 4-6. The study demonstrated a potentially effective treatment for patients with bladder cancer who no longer respond to the common therapy, Bacillus Calmette-Guérin (BCG). The novel treatment, cretostimogene grenadenorepvec, is an oncolytic immunotherapy, meaning it is a virus designed to selectively replicate in and break down…